Cancer Cell Research (Online ISSN: 2161-2609)
 |
Current Issue
Vol.2 No.5
Article: A Traditional Chinese Medicine Huaier Triggers G1 Cell Cycle Arrest and Apoptosis Through Cyclins-cdks-ckis Machinery in GIST-T1 Cells
by Yonghong Zhang, Yongxiang Li
Cancer Cell Research 2015 2(5) 105-110; published online 25 December 2014
Abstract:
It is well believed that cancer is a cell cycle dysfunction
disease, and most of chemotherapeutic reagents are targeting
proliferating cancer cells. Huaier, a traditional Chinese
medicine, has been extensively used as a kind of anti-cancer
drug in clinic for many years; however, the effect and
mechanism of its treatment on human cancer cells are still
unknown. In the current study, GIST-T1 cells treated with
Huaier were analyzed by flow cytometry to detect the cell
cycle distribution and cell apoptosis. In addition,
expression levels of cell-cycle regulators and apoptotic
proteins in response to DNA damage were examined by
immunoblotting. Our data showed that Huaier decreased the
viability of GIST-T1 by inducing G1 cell cycle arrest and
induced apoptosis in a dose- and time-dependent manner. In
GIST-T1 cells treated with Huaier, expression of cyclinD3/cyclinE
and Cdk2/Cdk4/Cdk6 proteins significantly decreased; in
contrast, expression of p16/p21/p27 proteins increased. Bax
protein also increased and Bcl-2 decreased after Huaier
treatment. Taken together, we firstly tested the biological
effect of Huaier on human cancer cells in vitro and further
probed its potential molecular targets, which provided the
direct evidence for its clinical application in cancer
patients.
Open Access Download (free) PDF
Article: Multi-slicespiral CT findings of Castleman’s disease
by Songsong Wang, Deceunynck C, Hamada M, Xiumei Chen, Jizheng Lin
Cancer Cell Research 2015 2(5) 111-114; published online 20 November 2014
Abstract:
This study is to find of Castleman's disease and the
diagnostic value of CT for Castleman’s disease. Clinical
data and CT of Castleman's disease of pathology cases were
retrospectively analyzed. The lesions were as follows:
middle mediastinum or hilum of lung (n=6), anterior and
posterior mediastinum (n=2). The clinical subtypes included
localized type in 7 cases and multicentric type in 1 case.
As for histopathologic classification, there were hyaline-vasculartype
in 7 cases and plasma cell type in 1 case. Apart from 2
cases with intra-tumoral calclfications, the other ones
showed homogeneous attenuation on plain CT. After contrast
administration, marked and sustained enhancement was showed
in hyaline vascular type, mild-moderate enhancement was
showed in plasma cell type. CT findings of Castleman’s
disease were closely correlated with pathological subtypes.
CT features of hyaline-vascular subtype are characteristic.
Open Access Download (free) PDF
Article: Expression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, in colorectal cancer
by Cheng Chi, Lulu Xu, Wensheng Qiu
Cancer Cell Research 2015 2(5) 115-119; published online 28 December 2014
Abstract:
Colorectal cancer is the third most common cancer and the
third leading cause of cancer-related death. VEGF165b has
been described as exerting anti-angiogenic activity. The aim
was to compare the expression of serum VEGF165b level in CRC
patients with paired normal serum samples and explore the
association between VEGF165b expression status and poor
pathological parameters. Pre-treatment serum samples were
available from 55 patients. The expression serum VEGF-165b
levels were analyzed by an ELISA. Group comparisons were
made using the independent samples t test. Serum samples
were analyzed from 55 colorectal cancer patients. Median
serum levels of VEGF-165b were significantly higher in
patients with lower stage (p=0.03), no lymph node metastases
(p=0.045) or Vascular invasion (p=0.026). Our data support
the role of VEGF165 b as a tumor suppressor factor in
colorectal carcinogenesis and its possible prognosis value.
Open Access Download (free) PDF
Article: Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A level in patients with metastatic colorectal cancer
by Lulu Xu, Cheng Chi, Congcong Wang, Liangming Zhang
Cancer Cell Research 2015 2(5) 120-124; published online 22 December 2014
Abstract:
Colorectal cancer is the third most common cancer and the
third leading cause of cancer-related death. Bevacizumab
improves survival for metastatic colorectal cancer patients
with chemotherapy, but no proven predictive markers exist.
The aim was to investigate the possible predictive value of
vascular endothelial growth factor (VEGF)-A levels in this
setting. Pre-treatment serum samples and response
evaluations were available from 20 patients. All patients
received bevacizumab and chemotherapy comprising
fluorouracil and leucovorin or capecitabine combined with
either oxaliplatin (FOLFOX or XELOX) or irinotecan (FOLFIRI
or IFL). The expression serum VEGF-A levels were analyzed by
an ELISA. Response was evaluated according to RECIST version
1.1, and group comparisons were made using the independent
sample test. The serum VEGF-A levels were 373.93±29.86pg/ml
and 294.22±35.53pg/ml in responders and non-responders
(p=0.101). There was no significant difference between them.
No correlation between the efficacy of bevacizumab-related
chemotherapy and serum VEGF-A levels was observed. In this
correlative evaluation, pretreatment serum VEGF-A levels
were not predictive for bevacizumab-based treatment benefit.
Open Access Download (free) PDF